We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

55 hedge funds and large institutions have $13.3M invested in Navidea Biopharmaceuticals Inc. in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more capital invested

Capital invested by funds: $10.7M → $13.3M (+$2.55M)

13% less funds holding

Funds holding: 63 → 55 (-8)

53% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 15

57% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 14

91% less call options, than puts

Call options by funds: $10K | Put options by funds: $116K

Holders
55
Holders Change
-8
Holders Change %
-12.7%
% of All Funds
1.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
7
Reduced
15
Closed
14
Calls
$10K
Puts
$116K
Net Calls
-$106K
Net Calls Change
-$77K

Top Buyers

Rank Fund Capital Flow
1
BIT
BlackRock Institutional Trust
California
+$924K
2
HIIFS
Harel Insurance Investments & Financial Services
Israel
+$190K
3
SIM
Spark Investment Management
New York
+$149K
4
Citadel Advisors
Citadel Advisors
Florida
+$34.7K
5
GC
Guggenheim Capital
Illinois
+$31.6K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$2.06M
2
PP
Paloma Partners
Connecticut
-$297K
3
Millennium Management
Millennium Management
New York
-$234K
4
LCM
Laurion Capital Management
New York
-$233K
5
CS
Credit Suisse
Switzerland
-$217K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
26
Guggenheim Capital
Illinois
$46K +$31.6K +2,496 New
Tudor Investment Corp
27
Tudor Investment Corp
Connecticut
$43K – – –
SW
28
SVB Wealth
Massachusetts
$42K – – –
TSS
29
Two Sigma Securities
New York
$36K +$24.7K +1,954 New
UBS Group
30
UBS Group
Switzerland
$32K -$59.4K -4,694 -73%
Commonwealth Equity Services
31
Commonwealth Equity Services
Massachusetts
$31K – – –
LFG
32
LifePlan Financial Group
Ohio
$26K – – –
BIM
33
BlackRock Investment Management
Delaware
$25K – – –
Bank of America
34
Bank of America
North Carolina
$24K -$34.3K -2,715 -67%
BA
35
BlackRock Advisors
Delaware
$24K – – –
Cambridge Investment Research Advisors
36
Cambridge Investment Research Advisors
Iowa
$22K +$4.43K +350 +42%
JCM
37
Jacobi Capital Management
Pennsylvania
$17K – – –
LA
38
Lynch & Associates
Indiana
$16K – – –
RJA
39
Raymond James & Associates
Florida
$16K – – –
SI
40
Stephens Inc
Arkansas
$14K – – –
Ameriprise
41
Ameriprise
Minnesota
$12K – – –
FAG
42
Financial Advisory Group
Texas
$11K – – –
Royal Bank of Canada
43
Royal Bank of Canada
Ontario, Canada
$10K – – –
B
44
Bailard
California
$9K – – –
CPIG
45
Chicago Partners Investment Group
Illinois
$3K – – –
JP Morgan Chase
46
JP Morgan Chase
New York
$2K -$13 -1 -0.7%
AG
47
Advisor Group
Arizona
$2K – – –
IA
48
IFP Advisors
Florida
$2K – – –
MFW
49
Mosaic Family Wealth
Missouri
$2K – – –
Simplex Trading
50
Simplex Trading
Illinois
$2K +$1.9K +150 New
1
2
3

NAVB Hedge Fund Activity: Q3 2016 in Review

55 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2016, worth a combined $13.3M — up 24% from $10.7M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of NAVB and 6 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 7 added.

The largest buyer was BlackRock Institutional Trust, adding an estimated $924K. The largest seller was Goldman Sachs, cutting an estimated $2.06M.

  • 55 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2016, down from 63 in Q2 2016.
  • Funds reported $13.3M of Navidea Biopharmaceuticals Inc. stock for Q3 2016, up 24% quarter-over-quarter.
  • 6 funds opened new Navidea Biopharmaceuticals Inc. positions in Q3 2016 and 14 closed out, a net change of -8 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2016 was BlackRock Institutional Trust, an estimated $924K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q3 2016 was Goldman Sachs, an estimated $2.06M sold.

Based on aggregated 13F filings for Q3 2016.